These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16435197)

  • 21. Alterations of membrane lipids and in gene expression of ganglioside metabolism in different brain structures in a mouse model of mucopolysaccharidosis type I (MPS I).
    Kreutz F; dos Santos Petry F; Camassola M; Schein V; Guma FC; Nardi NB; Trindade VM
    Gene; 2013 Sep; 527(1):109-14. PubMed ID: 23774686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
    Richard M; Arfi A; Seguin J; Gandolphe C; Scherman D
    Gene Ther; 2009 Jun; 16(6):746-56. PubMed ID: 19357715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene Therapy of Mucopolysaccharidosis Type I Mice: Repeated Administrations and Safety Assessment of pIDUA/Nanoemulsion Complexes.
    Fraga M; Schuh RS; Poletto É; de Carvalho TG; França RT; Pinheiro CV; Baldo G; Giugliani R; Teixeira HF; Matte U
    Curr Gene Ther; 2021; 21(5):464-471. PubMed ID: 33573568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased performance in IDUA knockout mouse mimic limitations of joint function and locomotion in patients with Hurler syndrome.
    Kim C; Kwak MJ; Cho SY; Ko AR; Rheey J; Kwon JY; Chung Y; Jin DK
    Orphanet J Rare Dis; 2015 Sep; 10():121. PubMed ID: 26407983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system.
    Aronovich EL; Bell JB; Khan SA; Belur LR; Gunther R; Koniar B; Schachern PA; Parker JB; Carlson CS; Whitley CB; McIvor RS; Gupta P; Hackett PB
    Mol Ther; 2009 Jul; 17(7):1136-44. PubMed ID: 19384290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
    Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
    Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
    Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
    PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphological damage in Sertoli, myoid and interstitial cells in a mouse model of mucopolysaccharidosis type I (MPS I).
    do Nascimento CC; Aguiar O; Viana GM; D'Almeida V
    Mol Biol Rep; 2021 Jan; 48(1):363-370. PubMed ID: 33319323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I.
    Wolf DA; Lenander AW; Nan Z; Braunlin EA; Podetz-Pedersen KM; Whitley CB; Gupta P; Low WC; McIvor RS
    Bone Marrow Transplant; 2012 Sep; 47(9):1235-40. PubMed ID: 22179554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model.
    Fraga M; de Carvalho TG; Bidone J; Schuh RS; Matte U; Teixeira HF
    Int J Nanomedicine; 2017; 12():2061-2067. PubMed ID: 28352175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
    Huang MM; Wong A; Yu X; Kakkis E; Kohn DB
    Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.
    Ma X; Liu Y; Tittiger M; Hennig A; Kovacs A; Popelka S; Wang B; Herati R; Bigg M; Ponder KP
    Mol Ther; 2007 May; 15(5):889-902. PubMed ID: 17311010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
    Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
    Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
    Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
    Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cationic Nanoemulsions as a Gene Delivery System: Proof of Concept in the Mucopolysaccharidosis I Murine Model.
    Fraga M; de Carvalho TG; Diel Dda S; Kretzmann Filho NA; Teixeira HF; Matte U
    J Nanosci Nanotechnol; 2015 Jan; 15(1):810-6. PubMed ID: 26328445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease.
    Squeri G; Passerini L; Ferro F; Laudisa C; Tomasoni D; Deodato F; Donati MA; Gasperini S; Aiuti A; Bernardo ME; Gentner B; Naldini L; Annoni A; Biffi A; Gregori S
    Mol Ther; 2019 Jul; 27(7):1215-1227. PubMed ID: 31060789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.
    Miyadera K; Conatser L; Llanga TA; Carlin K; O'Donnell P; Bagel J; Song L; Kurtzberg J; Samulski RJ; Gilger B; Hirsch ML
    Mol Ther; 2020 Jun; 28(6):1455-1463. PubMed ID: 32330426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.